Watanabe, Yoshiki
Mizuno, Kayoko
Kishimoto, Yo
Kawakami, Koji
Omori, Koichi
Article History
First Online: 28 April 2025
Disclosure
: Disclosure statement: Koji Kawakami has received research funds from AstraZeneca, Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Mitsubishi Corporation, OMRON Corporation, Real World Data Co., Ltd., Sumitomo Pharma Co., Ltd., and Toppan Inc.; consulting fees from Advanced Medical Care Inc., JMDC Inc., LEBER Inc., Ubicom Holdings, Inc., and Shin Nippon Biomedical Laboratories Ltd.; executive compensation from Cancer Intelligence Care Systems, Inc.; honoraria from Kaken Pharmaceutical Co., Ltd., Kyoto University Original Co., Ltd., Pharma Business Academy, Shionogi & Co., Ltd. Toppan Inc.; and held stock in Real World Data Co., Ltd. Kayoko Mizuno has been employed by the Department of Digital Health and Epidemiology with support from Eisai Co., Ltd. and Kyowa Kirin Co., Ltd. and has received grants from Japan Society for the Promotion of Science.